EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

Jie Ma iD, Caie Li iD, Wenjuan Wang iD, Xin Fan iD, Taotao Wei iD, Xin Ma iD, Yingdong Wang iD, Chuyan Feng iD, Jing Yu iD

Reviews in Cardiovascular Medicine · 12.03.2026 · 27 (3)

DOI: 10.31083/rcm44942 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 12.03.2026. Verfasst von Jie Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hypertension Center, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Gansu Province, Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Poly(ADP-ribose) polymerase (PARP) family comprises seventeen members that catalyze poly- or mono- adenosine diphosphate (ADP)-ribosylation, a pivotal post-translational modification regulating a wide array of cellular processes, including deoxyribonucleic acid (DNA) repair, apoptosis, protein synthesis, cellular proliferation, and responses to oxidative stress. PARP inhibitors (PARPIs) exhibit selective cytotoxicity in cancers with breast cancer susceptibility gene (BRCA) mutations or defects in homologous recombination. Activation of PARP, indicated by increased poly(ADP-ribose) (PAR) accumulation, is implicated in various disease states such as ischemia-reperfusion injury, vascular disorders, and diabetic complications. Clinically, PARPIs, in combination with anti-angiogenic therapies, not only show efficacy as monotherapies in epithelial ovarian cancer but also mitigate hypertension induced by anti-angiogenic agents. This review consolidates recent advancements in understanding the dual therapeutic potential of PARP inhibition, encompassing both antineoplastic and cardioprotective effects.

Schlagwörter

Stichwörter der Autor:innen

PARP1PARPIshypertensionvascular endothelial growth factor receptor inhibitors

Autor:innen und Institutionen

  • Department of Hypertension Center, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China.
  • Department of Cardiovascular Center, The First People's Hospital of Huzhou City, 313000 Huzhou, Zhejiang, China.

ORCID-Profile: Jie Ma, Caie Li, Wenjuan Wang, Xin Fan, Taotao Wei, Xin Ma, Yingdong Wang, Chuyan Feng, Jing Yu

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Department of Gansu Province
  • Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital
  • Special Fund Project for Doctoral Training of the Lanzhou University Second Hospital
  • International science and technology cooperation base

Zitieren

APA

Ma, J., Li, C., Wang, W., Fan, X., Wei, T., Ma, X., Wang, Y., Feng, C., & Yu, J. (2026). Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. Reviews in Cardiovascular Medicine, 27(3). https://doi.org/10.31083/rcm44942

Vancouver

Ma J, Li C, Wang W, Fan X, Wei T, Ma X, et al. Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. Reviews in Cardiovascular Medicine. 2026;27(3). doi:10.31083/rcm44942

BibTeX
@article{Ma2026,
  author = {Ma, Jie and Li, Caie and Wang, Wenjuan and Fan, Xin and Wei, Taotao and Ma, Xin and Wang, Yingdong and Feng, Chuyan and Yu, Jing},
  title = {Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors},
  journal = {Reviews in Cardiovascular Medicine},
  year = {2026},
  volume = {27},
  number = {3},
  doi = {10.31083/rcm44942}
}
Kostenlos starten →